Population pharmacokinetic modeling of plasma Δ9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration

被引:14
作者
Sempio, Cristina [1 ]
Huestis, Marilyn A. [5 ]
Mikulich-Gilbertson, Susan K. [3 ,4 ]
Klawitter, Jost [1 ]
Christians, Uwe [1 ]
Henthorn, Thomas K. [1 ,2 ]
机构
[1] Univ Colorado, Sch Med, Dept Anesthesiol, Campus Box B-113,12705 E Montview Blvd,Suite 200, Aurora, CO 80045 USA
[2] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Aurora, CO 80045 USA
[3] Univ Colorado, Sch Med, Dept Psychiat, Div Subst Dependence, Aurora, CO 80045 USA
[4] Univ Colorado, Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO 80045 USA
[5] Thomas Jefferson Univ, Inst Emerging Hlth Profess, Lambert Ctr Study Med Cannabis & Hemp, Philadelphia, PA 19107 USA
关键词
Delta; 9-tetrahydrocannabinol; THC; CB1; agonist; population pharmacokinetics; metabolite pharmacokinetics; BLOOD CANNABINOIDS; WHOLE-BLOOD; THC; DELTA(9)-TETRAHYDROCANNABINOL; BIOAVAILABILITY; IDENTIFICATION; DISPOSITION; FREQUENT; THCCOOH; TIME;
D O I
10.1111/bcp.14170
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Population pharmacokinetic models of Delta 9-tetrahydrocannabinol (THC) have been developed for THC plasma and blood concentration data. Often, only the metabolites of THC are measurable when blood samples are obtained. Therefore, we performed a population pharmacokinetic analysis of THC, 11-OH-THC and THCCOOH plasma concentration data from a Phase I clinical trial of THC smoking. Methods Frequently obtained plasma THC, 11-OH-THC and THCCOOH concentration data were obtained over 168 h from 6 subjects who smoked low (15.8 mg) and high dose (33.8 mg) THC cigarettes on 2 occasions. Bayesian estimates of the THC pharmacokinetic model from each individual for each dose were fixed prior to the sequential pharmacokinetic analysis of the metabolites. Results A 3-compartment model of THC was developed that has a steady-state volume of distribution (Vd(SS)) of 3401 +/- 788 L and a clearance of 0.72 +/- 0.10 L/min. 11-OH-THC was characterized by 50 +/- 6% of the THC being directly cleared to a 3-compartment model with a Vd(SS) of 415.2 +/- 4.3 L and clearance of 0.78 +/- 0.05 L/min. The THCCOOH model shared the central compartment of the 11-OH-THC model with a Vd(SS) of 29.1 +/- 0.05 L and a clearance of 0.12 +/- 0.02 L/min. First order kinetics were observed for THC and THCCOOH between the low and high doses, but a nonlinear pattern was observed for 11-OH-THC. Conclusion We describe the pharmacokinetics of THC, 11-OH-THC and THCCOOH including inter- and intraindividual variability of the parameter estimates of the model.
引用
收藏
页码:611 / 619
页数:9
相关论文
共 26 条
[1]   The Pharmacokinetics and Bioavailability of Prochlorperazine Delivered as a Thermally Generated Aerosol in a Single Breath to Volunteers [J].
Avram, M. J. ;
Spyker, D. A. ;
Henthorn, T. K. ;
Cassella, J. V. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (01) :71-77
[2]   Handling Data Below the Limit of Quantification in Mixed Effect Models [J].
Bergstrand, Martin ;
Karlsson, Mats O. .
AAPS JOURNAL, 2009, 11 (02) :371-380
[3]  
Bowling CM, 2019, AM J PUBLIC HEALTH, V109, P423, DOI [10.2105/AJPH.2018.304862, 10.2105/ajph.2018.304862]
[4]   Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi [J].
Desai, Amit ;
Kovanda, Laura ;
Kowalski, Donna ;
Lu, Qiaoyang ;
Townsend, Robert ;
Bonate, Peter L. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (09) :5483-5491
[5]   Phase I and II Cannabinoid Disposition in Blood and Plasma of Occasional and Frequent Smokers Following Controlled Smoked Cannabis [J].
Desrosiers, Nathalie A. ;
Himes, Sarah K. ;
Scheidweiler, Karl B. ;
Concheiro-Guisan, Marta ;
Gorelick, David A. ;
Huestis, Marilyn A. .
CLINICAL CHEMISTRY, 2014, 60 (04) :631-643
[6]  
DUTCHER JS, 1977, CLIN PHARMACOL THER, V22, P447
[7]   Pharmacokinetics and pharmacodynamics of cannabinoids [J].
Grotenhermen, F .
CLINICAL PHARMACOKINETICS, 2003, 42 (04) :327-360
[8]   Cannabis effects on driving longitudinal control with and without alcohol [J].
Hartman, Rebecca L. ;
Brown, Timothy L. ;
Milavetz, Gary ;
Spurgin, Andrew ;
Pierce, Russell S. ;
Gorelick, David A. ;
Gaffney, Gary ;
Huestis, Marilyn A. .
JOURNAL OF APPLIED TOXICOLOGY, 2016, 36 (11) :1418-1429
[9]   Population Pharmacokinetic Model of THC Integrates Oral, Intravenous, and Pulmonary Dosing and Characterizes Short- and Long-term Pharmacokinetics [J].
Heuberger, Jules A. A. C. ;
Guan, Zheng ;
Oyetayo, Olubukayo-Opeyemi ;
Klumpers, Linda ;
Morrison, Paul D. ;
Beumer, Tim L. ;
van Gerven, Joop M. A. ;
Cohen, Adam F. ;
Freijer, Jan .
CLINICAL PHARMACOKINETICS, 2015, 54 (02) :209-219
[10]   Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial [J].
Hjorthoj, Carsten Rygaard ;
Fohlmann, Allan ;
Larsen, Anne-Mette ;
Arendt, Mikkel ;
Nordentoft, Merete .
ADDICTION, 2012, 107 (06) :1123-1131